AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. Atlantic Securities dropped their price objective on AbbVie from $178.00 to $162.00 and set a "neutral" rating on the stock in a research note on Monday, August 1st. Piper Sandler cut their target price on AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. Daiwa Capital Markets lowered AbbVie from an "outperform" rating to a "neutral" rating and set a $150.00 target price on the stock. in a research report on Friday, May 6th. UBS Group cut their target price on AbbVie from $154.00 to $146.00 and set a "neutral" rating on the stock in a research report on Monday, August 1st. Finally, Wells Fargo & Company boosted their target price on AbbVie from $165.00 to $200.00 in a research report on Monday, May 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $160.50.

AbbVie Stock Down 0.6 %

NYSE:ABBV traded down $0.88 on Friday, reaching $138.04. The stock had a trading volume of 5,371,137 shares, compared to its average volume of 6,052,852. The business has a 50 day moving average price of $147.52 and a 200 day moving average price of $150.16. The company has a current ratio of 0.82, a quick ratio of 0.71 and a debt-to-equity ratio of 3.89. AbbVie has a 1 year low of $105.56 and a 1 year high of $175.91. The company has a market capitalization of $243.93 billion, a price-to-earnings ratio of 19.55, a P/E/G ratio of 3.87 and a beta of 0.70.

AbbVie (NYSE:ABBV - Get Rating) last released its quarterly earnings results on Friday, July 29th. The company reported $3.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.06. The company had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a return on equity of 157.31% and a net margin of 22.03%. The firm's revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.11 EPS. On average, analysts forecast that AbbVie will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be paid a dividend of $1.41 per share. The ex-dividend date is Thursday, July 14th. This represents a $5.64 annualized dividend and a dividend yield of 4.09%. AbbVie's dividend payout ratio (DPR) is presently 79.89%.

Insider Transactions at AbbVie

In other news, Vice Chairman Michael Severino sold 100,000 shares of the company's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the completion of the sale, the insider now owns 152,103 shares in the company, valued at approximately $23,492,308.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Vice Chairman Michael Severino sold 100,000 shares of the company's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the completion of the sale, the insider now owns 152,103 shares in the company, valued at approximately $23,492,308.35. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Henry O. Gosebruch sold 83,960 shares of the business's stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company's stock, valued at approximately $2,576,565. The disclosure for this sale can be found here. In the last quarter, insiders sold 363,761 shares of company stock worth $55,528,771. 0.08% of the stock is owned by corporate insiders.